| | | | | | | | D . 1 . |
|--------------|-------|------------|-----------|---------|---------------|------------|-----------------------|
| Oversientien | | Prevalence | 116.4.1.5 | BP | Medical | L in tal | Diabetes |
| Organization | | of Type 2 | HbA1c | | Attention for | Lipid | Care |
| Code | Track | Diabetes | Control | Control | Nephropathy | Management | Bundle |
| BC6 | Core | 20.3% | 49.0% | 57.3% | 79.2% | 69.6% | 29.7% |
| CJ7 | Core | 14.6% | 54.0% | 69.2% | 73.0% | 53.6% | 21.6% |
| CJ8 | Core | 13.9% | 59.1% | 62.2% | 83.5% | 72.7% | 24.9% |
| CM4 | Core | 14.9% | 63.9% | 70.6% | 85.7% | 68.8% | 30.6% |
| CN5 | Core | 11.1% | 71.4% | 81.4% | 89.2% | 72.4% | 45.0% |
| CR1 | Core | 7.0% | 72.5% | 75.2% | 84.9% | 53.7% | 33.0% |
| CZ4 | Core | 16.0% | 52.3% | 66.5% | 70.6% | 48.4% | 19.4% |
| DQ2 | Core | 16.9% | 63.2% | 77.7% | 93.7% | 80.5% | 40.3% |
| DR7 | Core | 17.4% | 72.0% | 79.8% | 92.5% | 98.7% | 55.9% |
| DV4 | Core | 24.0% | 54.7% | 62.3% | 89.0% | 61.2% | 21.9% |
| ED7 | Basic | 19.4% | 69.8% | | | | |
| ED9 | Core | 13.4% | 78.3% | 85.7% | 96.6% | 76.4% | 51.7% |
| EE2 | Core | 14.1% | 64.9% | 62.5% | 73.4% | 63.4% | 22.5% |
| EG1 | Core | 13.1% | 71.3% | 83.4% | 88.1% | 76.0% | 46.5% |
| EH2 | Core | 14.8% | 71.7% | 49.2% | 82.1% | 42.8% | 18.7% |
| EK2 | Core | 15.1% | 52.1% | 64.9% | 66.0% | 57.4% | 17.7% |
| EM3 | Core | 11.5% | 64.5% | 81.2% | 82.9% | 67.3% | 35.7% |
| EN9 | Core | 13.6% | 63.4% | 71.6% | 90.8% | 78.3% | 34.7% |
| EU5 | Core | 7.6% | 69.2% | 78.8% | 76.2% | 72.8% | 38.2% |
| FG7 | Core | 16.4% | 70.6% | 73.1% | 86.9% | 58.1% | 27.5% |
| FK7 | Core | 11.3% | 65.8% | 75.2% | 88.4% | 65.8% | 37.4% |
| FN3 | Basic | 22.0% | 55.1% | | | | |
| FV6 | Core | 8.5% | 62.5% | 67.9% | 83.3% | 59.6% | 27.5% |
| GB7 | Basic | 6.2% | 63.2% | | | | |
| GE4 | Core | 12.8% | 52.4% | 68.1% | 81.1% | 64.2% | 26.4% |

| | | Prevalence | | | Medical | | Diabetes |
|--------------|-------|------------|---------|---------|---------------|------------|----------|
| Organization | | of Type 2 | HbA1c | BP | Attention for | Lipid | Care |
| Code | Track | Diabetes | Control | Control | Nephropathy | Management | Bundle |
| GR5 | Core | 23.8% | 64.8% | 71.9% | 92.8% | 57.7% | 27.2% |
| GT1 | Core | 17.1% | 66.0% | 73.6% | 91.4% | 72.4% | 36.3% |
| JB1 | Core | 13.3% | 62.8% | 72.5% | 82.3% | 63.4% | 30.4% |
| JB6 | Core | 9.2% | 72.1% | 84.1% | 69.1% | 52.2% | 25.6% |
| JG2 | Basic | 15.0% | 60.6% | | | | |
| JH8 | Core | 24.1% | 75.5% | 77.0% | 91.6% | 75.9% | 37.4% |
| JM6 | Core | 15.4% | 52.6% | 67.1% | 78.3% | 59.3% | 23.0% |
| KJ5 | Core | 26.0% | 62.4% | 57.3% | 98.0% | 86.7% | 32.8% |
| KN3 | Core | 12.4% | 61.3% | 68.0% | 79.1% | 57.1% | 25.2% |
| KU8 | Core | 13.0% | 73.5% | 84.0% | 93.9% | 76.5% | 47.2% |
| LK5 | Core | 24.5% | 75.5% | 88.3% | 88.4% | 63.8% | 35.7% |
| LM2 | Core | 14.5% | 33.9% | 63.3% | 78.5% | 57.6% | 12.7% |
| LV2 | Basic | 7.7% | 59.8% | | | | |
| LY2 | Core | 15.7% | 63.1% | 78.5% | 77.2% | 60.5% | 27.7% |
| MC2 | Core | 8.8% | 64.4% | 64.8% | 93.5% | 38.7% | 17.0% |
| ME5 | Core | 9.6% | 64.2% | 53.3% | 85.8% | 72.4% | 26.6% |
| ML7 | Core | 10.9% | 53.2% | 68.9% | 78.9% | 63.6% | 27.0% |
| ND4 | Core | 14.0% | 63.2% | 71.3% | 90.8% | 71.6% | 33.4% |
| NS5 | Core | 18.7% | 65.4% | 71.1% | 76.9% | 66.5% | 28.4% |
| PB9 | Core | 12.1% | 53.9% | 77.5% | 86.6% | 54.6% | 5.8% |
| PE8 | Core | 12.0% | 64.2% | 81.6% | 89.2% | 72.9% | 37.9% |
| PQ6 | Core | 11.2% | 77.9% | 90.1% | 92.0% | 80.5% | 56.4% |
| PT8 | Core | 9.5% | 59.5% | 77.8% | 83.7% | 70.2% | 35.2% |
| QB1 | Core | 25.0% | 68.8% | 74.5% | 93.9% | 37.2% | 18.8% |
| QC4 | Core | 18.7% | 69.7% | 65.0% | 88.3% | 69.0% | 33.0% |

| | | Prevalence | | | Medical | | Diabetes |
|--------------|-------|------------|---------|---------|---------------|------------|----------|
| Organization | | of Type 2 | HbA1c | BP | Attention for | Lipid | Care |
| Code | Track | Diabetes | Control | Control | Nephropathy | Management | Bundle |
| QF1 | Core | 14.5% | 66.0% | 74.5% | 80.8% | 61.9% | 32.3% |
| QH1 | Core | 12.0% | 66.2% | 75.3% | 89.1% | 69.9% | 35.1% |
| QJ2 | Basic | 11.2% | 68.6% | | | | |
| QP8 | Core | 9.5% | 80.7% | 94.4% | 90.6% | 64.3% | 48.0% |
| QR4 | Core | 16.0% | 67.0% | 72.8% | 78.7% | 60.2% | 27.2% |
| SB2 | Basic | 12.5% | 58.5% | | | | |
| SD9 | Core | 12.7% | 47.4% | 57.5% | 80.7% | 73.1% | 23.2% |
| SE2 | Core | 13.1% | 65.3% | 79.8% | 84.1% | 73.8% | 36.4% |
| SJ9 | Core | 16.9% | 65.1% | 70.4% | 86.8% | 67.7% | 33.2% |
| SQ3 | Core | 15.4% | 49.5% | 73.7% | 71.8% | 68.3% | 25.4% |
| TE7 | Core | 13.7% | 69.8% | 64.5% | 93.0% | 64.7% | 31.4% |
| UE5 | Core | 15.4% | 75.7% | 70.1% | 58.3% | 47.9% | 17.4% |
| UG9 | Core | 14.3% | 71.7% | 80.6% | 89.2% | 72.9% | 43.7% |
| UH4 | Core | 17.3% | 66.7% | 70.8% | 78.6% | 61.4% | 31.6% |
| UP3 | Core | 11.3% | 58.4% | 69.8% | 78.9% | 64.8% | 28.1% |
| UQ1 | Basic | 27.2% | 38.2% | | | | |
| UQ5 | Core | 12.5% | 62.5% | 65.7% | 90.7% | 70.2% | 29.8% |
| UY8 | Core | 13.1% | 71.8% | 82.2% | 90.5% | 77.5% | 46.5% |
| VD1 | Core | 8.5% | 78.4% | 88.2% | 72.3% | 66.6% | 37.3% |
| VD3 | Basic | 13.5% | 56.5% | | | | |
| VG5 | Core | 14.8% | 65.9% | 73.8% | 89.5% | 63.6% | 31.6% |
| VK4 | Basic | 19.1% | 67.2% | | | | |
| VP7 | Core | 8.8% | 65.6% | 65.4% | 83.4% | 64.8% | 30.5% |
| VR4 | Basic | 11.9% | 79.4% | | | | |
| VX4 | Core | 3.8% | 77.9% | 83.0% | 85.5% | 68.1% | 38.4% |

| Organization | | Prevalence of Type 2 | HbA1c | BP | Medical Attention for | Lipid | Diabetes Care |
|--------------|-------|-------------------------|---------|---------|--------------------------|------------|------------------|
| Code | Track | Diabetes | Control | Control | Nephropathy | Management | Bundle |
| WB8 | Core | 10.6% | 61.4% | 73.0% | 75.4% | 69.8% | 30.2% |
| WP3 | Core | 8.6% | 55.3% | 74.6% | 83.5% | 63.7% | 28.3% |
| WP8 | Core | 9.2% | 53.8% | 80.4% | 74.6% | 69.8% | 30.9% |
| WR4 | Core | 15.1% | 60.9% | 71.3% | 80.1% | 59.8% | 23.5% |
| WX4 | Core | 6.7% | 70.4% | 71.0% | 89.7% | 67.0% | 34.9% |
| WX9 | Core | 5.3% | 68.1% | 66.9% | 71.9% | 63.0% | 26.6% |
| XB5 | Core | 16.9% | 67.6% | 70.7% | 79.8% | 64.2% | 32.8% |
| XH9 | Core | 6.6% | 67.8% | 77.8% | 91.2% | 70.6% | 39.5% |
| XK8 | Core | 7.0% | 74.8% | 80.6% | 91.4% | 79.9% | 47.5% |
| XW5 | Core | 15.8% | 54.8% | 69.3% | 73.3% | 62.0% | 26.5% |
| XX3 | Core | 11.1% | 60.5% | 77.6% | 82.1% | 65.5% | 33.1% |
| XZ1 | Core | 14.1% | 66.2% | 70.5% | 90.5% | 70.6% | 35.8% |
| YB4 | Core | 13.9% | 70.1% | 83.4% | 93.7% | 72.4% | 42.2% |
| YM4 | Core | 9.2% | 68.8% | 70.2% | 92.9% | 76.6% | 37.4% |
| YP8 | Core | 9.6% | 68.9% | 66.9% | 89.9% | 65.5% | 31.7% |
| YX5 | Core | 17.3% | 67.2% | 72.8% | 90.1% | 71.4% | 37.5% |
| YZ3 | Core | 18.6% | 67.6% | 70.4% | 82.0% | 63.7% | 31.0% |
| ZD8 | Core | 12.9% | 54.7% | 69.1% | 84.4% | 69.2% | 30.0% |
| ZJ9 | Core | 13.5% | 59.0% | 63.5% | 68.1% | 32.4% | 10.4% |
| ZT2 | Core | 11.1% | 69.4% | 70.7% | 84.1% | 72.6% | 35.4% |